MX2016015389A - Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo. - Google Patents
Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo.Info
- Publication number
- MX2016015389A MX2016015389A MX2016015389A MX2016015389A MX2016015389A MX 2016015389 A MX2016015389 A MX 2016015389A MX 2016015389 A MX2016015389 A MX 2016015389A MX 2016015389 A MX2016015389 A MX 2016015389A MX 2016015389 A MX2016015389 A MX 2016015389A
- Authority
- MX
- Mexico
- Prior art keywords
- human
- cynomolgus
- antibody
- epsilon
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14170140 | 2014-05-28 | ||
| EP14180572 | 2014-08-11 | ||
| PCT/EP2015/061457 WO2015181098A1 (en) | 2014-05-28 | 2015-05-22 | Antibodies binding to human and cynomolgus cd3 epsilon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016015389A true MX2016015389A (es) | 2017-04-13 |
Family
ID=53268799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016015389A MX2016015389A (es) | 2014-05-28 | 2015-05-22 | Anticuerpos que se enlazan a cd3 epsilon humano y de mono cinomolgo. |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20170233475A1 (enExample) |
| EP (2) | EP3149041A1 (enExample) |
| JP (1) | JP6738285B2 (enExample) |
| KR (1) | KR20170003591A (enExample) |
| CN (1) | CN106459201A (enExample) |
| AU (1) | AU2015266077A1 (enExample) |
| BR (1) | BR112016022819A2 (enExample) |
| CA (1) | CA2942453A1 (enExample) |
| IL (1) | IL247740A0 (enExample) |
| MX (1) | MX2016015389A (enExample) |
| RU (1) | RU2016151235A (enExample) |
| SG (1) | SG11201609950YA (enExample) |
| WO (1) | WO2015181098A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016368469B2 (en) | 2015-12-09 | 2023-11-02 | F. Hoffmann-La Roche Ag | Type II anti-CD20 antibody for reducing formation of anti-drug antibodies |
| WO2017150762A1 (ko) * | 2016-02-29 | 2017-09-08 | (주)메디톡스 | 항-CD3γε 항체 및 이의 용도 |
| EP3252078A1 (en) | 2016-06-02 | 2017-12-06 | F. Hoffmann-La Roche AG | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| CN110603266A (zh) | 2016-06-02 | 2019-12-20 | 豪夫迈·罗氏有限公司 | 用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体 |
| ES3039621T3 (en) * | 2016-12-22 | 2025-10-23 | Daiichi Sankyo Co Ltd | Anti-cd3 antibody, and molecule containing said antibody |
| EP3409322A1 (en) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| WO2018224441A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
| AU2018280681B2 (en) * | 2017-06-05 | 2025-01-23 | Numab Therapeutics AG | Novel anti-CD3 antibodies |
| TWI728250B (zh) | 2017-06-21 | 2021-05-21 | 美商基利科學股份有限公司 | 靶向hiv gp120及cd3之多特異性抗體 |
| US12486325B2 (en) | 2017-09-21 | 2025-12-02 | WuXi Biologics Ireland Limited | Anti-CD3epsilon antibodies |
| MY199530A (en) | 2017-09-21 | 2023-11-03 | Wuxi Biologics Ireland Ltd | Anti-cd3epsilon antibodies |
| CN111417719B (zh) | 2017-11-30 | 2023-08-29 | 豪夫迈·罗氏有限公司 | B细胞培养方法 |
| CN120399075A (zh) * | 2018-03-14 | 2025-08-01 | 诺维莫尼公司 | 抗-CD3ε抗体及其应用方法 |
| CN112912397B (zh) | 2018-05-24 | 2025-03-14 | 詹森生物科技公司 | 抗cd3抗体及其用途 |
| TW202016144A (zh) * | 2018-06-21 | 2020-05-01 | 日商第一三共股份有限公司 | 包括cd3抗原結合片段之組成物及其用途 |
| CA3184189A1 (en) * | 2020-05-27 | 2021-12-02 | Janssen Biotech, Inc. | Proteins comprising cd3 antigen binding domains and uses thereof |
| IL301276A (en) * | 2020-09-24 | 2023-05-01 | Morphosys Ag | Novel human antibodies that bind to human CD3-epsilon |
| CN114656562B (zh) * | 2020-12-23 | 2023-11-03 | 北京天广实生物技术股份有限公司 | 结合人和猴cd3的抗体及其应用 |
| US12258406B2 (en) | 2021-03-24 | 2025-03-25 | Twist Bioscience Corporation | Antibodies that bind CD3 Epsilon |
| WO2022228705A1 (en) | 2021-04-30 | 2022-11-03 | F. Hoffmann-La Roche Ag | Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate |
| AU2021443863A1 (en) | 2021-04-30 | 2023-10-26 | F. Hoffmann-La Roche Ag | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody |
| CN115536740A (zh) * | 2021-06-30 | 2022-12-30 | 苏州方德门达新药开发有限公司 | 介导细胞内有效滞留cd3的空间构象表位及其应用 |
| CN113755435B (zh) * | 2021-10-15 | 2023-10-13 | 苏州药明康德新药开发有限公司 | 一种食蟹猴pbmc分离方法 |
| WO2023183766A1 (en) * | 2022-03-20 | 2023-09-28 | Abcellera Biologics Inc. | Anti-cd3 antibodies and t-cell engagers and methods of use |
| CA3246381A1 (en) * | 2022-03-22 | 2023-09-28 | Morphosys Ag | CD3-SPECIFIC DEIMMUNEIZED ANTIBODIES |
| WO2023180353A1 (en) | 2022-03-23 | 2023-09-28 | F. Hoffmann-La Roche Ag | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
| CA3255366A1 (en) | 2022-04-13 | 2023-10-19 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions based on bispecific anti-CD20/anti-CD3 antibodies and methods of use |
| WO2024088987A1 (en) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Combination therapy for the treatment of cancer |
| WO2026006492A2 (en) | 2024-06-25 | 2026-01-02 | Ypsilon Therapeutics, Inc. | Anti-prame/hla-a2 antibodies and uses thereof |
| WO2026006495A1 (en) | 2024-06-25 | 2026-01-02 | Alloy Therapeutics, Inc. | Anti-wt1/hla-a2 antibody and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD272473B3 (de) * | 1988-06-13 | 1993-01-21 | Univ Leipzig | Verfahren zur herstellung monoklonaler antikoerper gegen die epsilon-kettedes cd 3-antigens humaner t-lymphozyten |
| JPH0630786A (ja) * | 1992-07-14 | 1994-02-08 | Kyowa Hakko Kogyo Co Ltd | バイスペシフィック抗体 |
| MXPA06014075A (es) * | 2004-06-03 | 2007-03-15 | Novimmune Sa | Anticuerpos anti-cd3 y metodos de uso de los mismos. |
| JP5686953B2 (ja) * | 2005-10-11 | 2015-03-18 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハー | 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用 |
| JP2010524435A (ja) * | 2007-04-03 | 2010-07-22 | マイクロメット アーゲー | 種間特異的二重特異性バインダー |
| WO2012158818A2 (en) * | 2011-05-16 | 2012-11-22 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| US9587021B2 (en) * | 2011-05-21 | 2017-03-07 | Macrogenics, Inc. | CD3-binding molecules capable of binding to human and non-human CD3 |
| WO2015172800A1 (en) * | 2014-05-12 | 2015-11-19 | Numab Ag | Novel multispecific molecules and novel treatment methods based on such multispecific molecules |
-
2015
- 2015-05-22 RU RU2016151235A patent/RU2016151235A/ru not_active Application Discontinuation
- 2015-05-22 WO PCT/EP2015/061457 patent/WO2015181098A1/en not_active Ceased
- 2015-05-22 AU AU2015266077A patent/AU2015266077A1/en not_active Abandoned
- 2015-05-22 BR BR112016022819A patent/BR112016022819A2/pt not_active Application Discontinuation
- 2015-05-22 MX MX2016015389A patent/MX2016015389A/es unknown
- 2015-05-22 EP EP15725002.8A patent/EP3149041A1/en not_active Ceased
- 2015-05-22 SG SG11201609950YA patent/SG11201609950YA/en unknown
- 2015-05-22 CA CA2942453A patent/CA2942453A1/en not_active Abandoned
- 2015-05-22 CN CN201580026998.5A patent/CN106459201A/zh active Pending
- 2015-05-22 JP JP2016569639A patent/JP6738285B2/ja not_active Expired - Fee Related
- 2015-05-22 EP EP20163877.2A patent/EP3763739A1/en not_active Withdrawn
- 2015-05-22 KR KR1020167033022A patent/KR20170003591A/ko not_active Withdrawn
-
2016
- 2016-09-11 IL IL247740A patent/IL247740A0/en unknown
- 2016-11-22 US US15/359,199 patent/US20170233475A1/en not_active Abandoned
-
2020
- 2020-01-23 US US16/751,046 patent/US20200325224A1/en not_active Abandoned
- 2020-01-23 US US16/751,062 patent/US20200299385A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015266077A1 (en) | 2016-09-29 |
| US20200325224A1 (en) | 2020-10-15 |
| RU2016151235A3 (enExample) | 2019-01-18 |
| JP6738285B2 (ja) | 2020-08-12 |
| BR112016022819A2 (pt) | 2018-01-16 |
| EP3763739A1 (en) | 2021-01-13 |
| RU2016151235A (ru) | 2018-06-28 |
| CN106459201A (zh) | 2017-02-22 |
| SG11201609950YA (en) | 2016-12-29 |
| US20200299385A1 (en) | 2020-09-24 |
| KR20170003591A (ko) | 2017-01-09 |
| WO2015181098A1 (en) | 2015-12-03 |
| CA2942453A1 (en) | 2015-12-03 |
| IL247740A0 (en) | 2016-11-30 |
| JP2017516786A (ja) | 2017-06-22 |
| EP3149041A1 (en) | 2017-04-05 |
| US20170233475A1 (en) | 2017-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016022819A2 (pt) | uso de um método, método para a produção de um anticorpo com reatividade cruzada para humano e cinomolgo e anticorpo com reatividade cruzada para humano e cinomolgo | |
| ZA202211057B (en) | Anti-trem2 antibodies and methods of use thereof | |
| EP3991748A3 (en) | Anti-sortilin antibodies and methods of use thereof | |
| WO2017075432A3 (en) | Anti-siglec-9 antibodies and methods of use thereof | |
| PH12021550041A1 (en) | Anti-sortilin antibodies and methods of use thereof | |
| MX2020003046A (es) | Anticuerpos anti-hla-a2 y metodos para utilizar los mismos. | |
| WO2017062672A3 (en) | Anti-trem2 antibodies and methods of use thereof | |
| IL317134A (en) | An antibody containing only heavy chains that binds a human B-cell maturation antigen, a pharmaceutical composition containing the same, its use in the treatment of B-cell disorders and a method for its preparation | |
| WO2016201389A3 (en) | Anti-cd33 antibodies and methods of use thereof | |
| WO2016201388A3 (en) | Anti-cd33 antibodies and methods of use thereof | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| NZ603226A (en) | Anti-c5a antibodies and methods for using the antibodies | |
| MX2022007774A (es) | Anticuerpos de union a abril modificados. | |
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| NZ714516A (en) | Human antibodies to clostridium difficile toxins | |
| MX2020013324A (es) | Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos. | |
| NZ607969A (en) | Cd33 binding agents | |
| MX341958B (es) | Anticuerpos contra el il33r humano y usos de los mismos. | |
| AU2014236098A8 (en) | Treatment of cancer using humanized anti-CD19 chimeric antigen receptor | |
| WO2015173756A3 (en) | Bispecific antibodies with engineered ch1-cl interfaces | |
| JP2017516786A5 (enExample) | ||
| MX384246B (es) | POLIPÉPTIDO DE UNIÓN A TCR ALFA BETA PARA USARSE EN LA DISMINUCIÓN DE LINFOCITOS TAß. | |
| WO2021203030A3 (en) | Methods of use of anti-trem2 antibodies | |
| WO2013064700A3 (en) | Chimeric human-camel antigens and their use | |
| PH12022550239A1 (en) | Anti-ms4a4a antibodies and methods of use thereof |